維維股份(600300.SH):公司產品在豆奶領域處於行業領軍地位
格隆匯6月29日丨維維股份(600300.SH)在2023年6月29日業績説明會上表示,報吿期內,公司主要從事豆奶粉、植物蛋白飲料、乳品、茶葉等系列產品的研發、生產和銷售,以及糧食收購、倉儲、貿易、加工業務。旗下擁有“維維”豆奶粉、“維維”豆漿粉、“維維”穀物麥片、“維維”藕粉、“維維”液態豆奶、“維維六朝松”麪粉、“天山雪”乳品、“怡清源”茶葉等系列產品。公司秉持健康理念,恪守匠心精神,持續精耕豆奶領域30年,“維維豆奶,歡樂開懷”家喻户曉,“維維”品牌深入人心,“維維”產品廣受青睞,公司產品在豆奶領域處於行業領軍地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.